SCHEMBL19702459

SCHEMBL19702459

COc1ncccc1OC1CCN(C(=O)COc2ccc(CO)cc2)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 2/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ GAA P10253 2/20 0.45
▸ MAPT P10636 2/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ PIK3CD O00329 7/20 0.45
▸ PIK3CA P42336 6/20 0.45
▸ GRIN1 Q05586 1/20 0.44
▸ GRIN2B Q13224 1/20 0.44
▸ GPR6 P46095 1/20 0.43
▸ POLB P06746 3/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19702243 0.92 POLB (0.43) RAB9AALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL19702388 0.91 ALDH1A1 (0.42) RAB9AALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL19702405 0.89 ALDH1A1 (0.44) RAB9AALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL19702397 0.88 ALDH1A1 (0.44) RAB9AALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL19702389 0.88 MAPT (0.49) RAB9AALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL19702253 0.88 DGAT2 (0.46) RAB9AALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL19702763 0.87 ALDH1A1 (0.49) RAB9AALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL19702649 0.87 ALDH1A1 (0.49) RAB9AALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL19702650 0.87 ALDH1A1 (0.49) RAB9AALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL19702393 0.86 ALDH1A1 (0.45) RAB9AALDH1A1GAAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200306248-A1 FORMULATIONS FOR SUBSTITUTED 3-PYRROLIDINES, COMPOSITIONS CONTAINING, AND USES OF, SAME GDD THERAPEUTICS, LLC (US) 2020-10-01 — — US disclosed
WO-2017214201-A1 FORMULATIONS FOR SUBSTITUTED 3-PYRROLIDINES, COMPOSITIONS CONTAINING, AND USES OF, SAME THESAN PHARMACEUTICALS, INC. (US) 2017-12-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200306248-A1 FORMULATIONS FOR SUBSTITUTED 3-PYRROLIDINES, COMPOSITIONS CONTAINING, AND USES OF, SAME SLC7A1, ABCG2, SLC46A1 RAB9A 1275/4885ALDH1A1 931/4885GAA 108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback